{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T06:11:14Z","timestamp":1700547074913},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,5,26]],"date-time":"2009-05-26T00:00:00Z","timestamp":1243296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> We have shown previously that PEGylated liposomes (PEGLip) bind recombinant FVIII (rFVIII) with high affinity and specificity. This binding resulted in a significant extension of the biological activity of rFVIII as demonstrated in animal models and in clinical trials. In the present study we found that PEGLip bind plasma\u2010derived factor VIII (pdFVIII). PEGLip binding did not affect potency or stability <jats:italic>in vitro<\/jats:italic> and did not alter levels of FVIII activity <jats:italic>in vivo<\/jats:italic> immediately after injection. However, formulation of pdFVIII with PEGLip led to several important improvements. Twenty\u2010four and 30\u2003hours after injection, FVIII activity levels were significantly higher in haemophilic mice injected with PEGLip\u2010pdFVIII than in mice injected with standard pdFVIII. Half life, area under the curve and mean residence time were increased while clearance was decreased. <jats:italic>In vivo<\/jats:italic> efficacy was evaluated in a tail vein transection assay performed in haemophilic mice. Prophylactic treatment with PEGLip\u2010pdFVIII was much more effective in prolonging survival in this assay than similar treatment with standard pdFVIII. These results suggest that formulation of pdFVIII with PEGLip has the potential to improve patient care by prolonging the biological efficacy of pdFVIII and reducing the frequency of FVIII infusions.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2009.02045.x","type":"journal-article","created":{"date-parts":[[2009,5,27]],"date-time":"2009-05-27T03:54:32Z","timestamp":1243396472000},"page":"1006-1013","source":"Crossref","is-referenced-by-count":13,"title":["Enhancement of haemostatic efficacy of plasma\u2010derived FVIII by formulation with PEGylated liposomes"],"prefix":"10.1111","volume":"15","author":[{"given":"I.","family":"DAYAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"ROBINSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"BARU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,8,26]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"135","volume-title":"Hemostasis and Thrombosis: Basic Principles and Clinical Practice","author":"Kaufman R","year":"2001"},{"key":"e_1_2_7_3_2","first-page":"815","volume-title":"Hemostasis and Thrombosis: Basic Principles and Clinical Practice","author":"Arun B","year":"2001"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00254977"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1118\/1.595079"},{"key":"e_1_2_7_6_2","first-page":"103","volume-title":"Stealth Liposomes","author":"Woodle MC","year":"1995"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4157(92)90038-C"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(97)00136-1"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1160\/TH04-08-0485","article-title":"Factor VIII efficient and specific non\u2010covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy","volume":"93","author":"Baru M","year":"2005","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01741.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2008.12.004"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-008276"},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1160\/TH08-03-0133","article-title":"Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A","volume":"100","author":"Spira J","year":"2008","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2007.00892.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2007.04.008"},{"key":"e_1_2_7_16_2","first-page":"1288","article-title":"Immune tolerance induction with highly purified plasma\u2010derived factor VIII containing von Willebrand factor in hemophilia A patients with high\u2010responding inhibitors","volume":"90","author":"Orsini F","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11438"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0595-119"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615666"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-05-0361"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02937415"},{"key":"e_1_2_7_22_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1055\/s-0037-1614009","article-title":"Activity of a sub\u2010cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis","volume":"84","author":"Berry CN","year":"2000","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-03-0201"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1081\/BIO-120025410"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01502.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2009.02045.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2009.02045.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:24:40Z","timestamp":1697387080000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2009.02045.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,26]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1111\/j.1365-2516.2009.02045.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02045.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,26]]}}}